Announcements Trials

Browse Landscape

Phase

Phase 3 2 Phase 1/2 1 Phase 1 1

Status

Recruiting 10 Active not recruiting 5 Completed 4 Terminated 3 Withdrawn 1 Unknown 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

HER2 Negative Breast Cancer Not Immediately Operated 1

Interventions

Cyclophosphamide 28 pembrolizumab 22 Bevacizumab 18 Fluorouracil 17 Cisplatin 17 Nivolumab 16 Capecitabine 16 Leucovorin 15 Dexamethasone 14 Carboplatin 13 avelumab 12 Oxaliplatin 12 Radiosurgery 11 Gemcitabine 11 Rituximab 10 Radiotherapy 10 Lenalidomide 10 ALT-803 10 venetoclax 9 fludarabine 9 Taxes 9 Omacor 9 Azacitidine 9 130-nm albumin-bound paclitaxel 9 Paclitaxel 8 Docetaxel 8 Bortezomib 8 fludarabine phosphate 7 Melphalan 7 Irinotecan 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Withdrawn × ribociclib × Clear all

NCT05664893 2026-04-15

CALHYS

Centre Antoine Lacassagne

Phase 1/2 Withdrawn

HER2 Negative Breast Cancer Not Immediately Operated

Data powered by HemOnc (CC BY 4.0) Colophon ⚡